Scientists have been racing the clock to battle Methicillin-resistant Staphylococcus aureus (MRSA), a bacterium that shows resistance to our strongest antibiotics. An overwhelming number of patients are picking up this deadly bug while in hospitals for unrelated illnesses or injury.
Cleanliness and hygiene have become a paramount concern in the recent years, but even with the strictest of health codes, the bacterium claims roughly 100,000 lives in the US per year (with about 1,000,000 infected)
Dr. Blake Adams out of Greenfield, PA may have the answer to fighting this deadly outbreak.
Dr. Adams has begun infecting his patients with active esophageal cancer cells in an attempt to attack the bug. With a 5 year survival rate of nearly 40% in esophageal cancer patients, the prognosis is much greater than if the MRSA were allowed to run rampant alone or even with conventional antibiotics.
“The trick is to try and kill the MRSA with the active cancer cells, and then begin radiation as soon as the patient tests MRSA free,” Dr. Adams explains, “the patient needs to begin chemotherapy before the cancer metastasizes and while it is still located only in the esophagus.”
Adams says that although the long term prognosis is generally less than a 10 year survival rate, his current patients tend to choose the cancer route over the fast-paced MRSA prognosis. “I give my patients hope,” he says, “most would rather a definitive 10 years of life than a potential 10 days left of life. With a 10 year prognosis, they can say goodbye to family and tie up loose ends. Most prefer that route.”
His research is ongoing, however his ground-breaking discovery may be the next step in battling many different types of deadly bacteria and viruses